GH’s Phase IIb Data Show Potential Differentiation In Depression

 
• By Joseph Haas

Seeking to bring its psychedelic candidate to market in treatment-resistant depression, Ireland’s GH sees its drug-device inhalation combo product as offering strong differentiation versus Spravato.

GH Research hopes to soon start Phase III in treatment-resistant depression

More from Clinical Trials

More from Therapy Areas